Navigation Links
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
Date:9/24/2008

are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the FDG-PET clinical

trial;

-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item IA "Risk Factors" in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2007 on file

with the SEC.

All forward-looking statements attributable to us or persons acting
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Egalet Corporation (Nasdaq: EGLT ) ... on developing, manufacturing and marketing innovative pain treatments, ... and chief executive officer, is scheduled to present ... an update on Egalet,s marketed product SPRIX ... product OXAYDO ™ (oxycodone HCI, USP) tablets ...
(Date:5/26/2015)... , UAE, May 26, 2015 ... Patient Care & Quality of Life Throughout Europe, the ... Africa    Astellas Pharma EMEA is ... the Company,s founding through the historic merger of Japanese ... last ten years, committed to turning science into value ...
(Date:5/22/2015)... 22, 2015  Research and Benchmarking firm, Best ... Medical Affairs Roundtable on Thursday, May 28th ... roundtable to discuss "Medical Affairs, Role in Health ... Medical Affairs Consortium provides Medical Affairs leaders with ... challenges they face. The consortium has developed a ...
Breaking Medicine Technology:Egalet to Present at Upcoming Conferences in June 2Egalet to Present at Upcoming Conferences in June 3Astellas Pharma EMEA Celebrates Its 10th Anniversary 2Astellas Pharma EMEA Celebrates Its 10th Anniversary 3Astellas Pharma EMEA Celebrates Its 10th Anniversary 4Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2
... organizations can now gain unmatched visibility into their business ... costs, ensure compliance, and improve financial performance with new ... Inc. (AIM: CRW.L; OTC: CRWRY), the leader in ... "Pharmacy revenue leakage costs hospitals millions," said Keith ...
... Pharmaceuticals, Inc., (Amex: AEN ) announced five ... zinc deficiency in Alzheimer,s disease and cognitive decline. The ... and consultant, George J. Brewer, M.D., the Morton S. ... Internal Medicine at the University of Michigan. ...
Cached Medicine Technology:Craneware's Pharmacy ChargeLink® Version 3 Helps Improve Margins and Control Costs 2Craneware's Pharmacy ChargeLink® Version 3 Helps Improve Margins and Control Costs 3Craneware's Pharmacy ChargeLink® Version 3 Helps Improve Margins and Control Costs 4Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimer's Disease and Cognitive Decline 2Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimer's Disease and Cognitive Decline 3Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimer's Disease and Cognitive Decline 4Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimer's Disease and Cognitive Decline 5
(Date:5/26/2015)... Boston, MA. (PRWEB) May 26, 2015 ... Standing option in their online Master of Social ... Program sites and on the Charles River Campus, the ... , This Advanced Standing option is open ... by the Council on Social Work Education. Students entering ...
(Date:5/26/2015)... 26, 2015 Carl W. Berk, M.D. ... Center in Pinehurst, N.C. have launched a Balloon Sinuplasty ... about chronic sinusitis and the benefits of Balloon Sinuplasty. ... used to determine if someone is a good candidate ... and other factors that can contribute to chronic nasal ...
(Date:5/25/2015)... La. (PRWEB) May 26, 2015 Author Vincent ... number of people today are overweight, and many of them ... health. He also knows that most people don’t realize the ... environmental hazards and man-made toxins that exist. There ... don’t realize exactly how serious tobacco is.” , In “ ...
(Date:5/25/2015)... (PRWEB) May 26, 2015 ... honors Dr. Heather Stanley-Christian as a ... Year Circle. She is recognized with this prestigious ... nation's leading networking organization exclusively for professional women, ... operating local chapters. , "I'm pleased to welcome ...
(Date:5/25/2015)... New York (PRWEB) May 25, 2015 ... of patented products, launches the Big Little Party Table, ... customize the perfect table that will suit their party ... whopping revenue of $646 billion this past year. ... year industry" says Scott J. Cooper, CEO and Creative ...
Breaking Medicine News(10 mins):Health News:Boston University to Offer Online Master of Social Work Advanced Standing Option 2Health News:Boston University to Offer Online Master of Social Work Advanced Standing Option 3Health News:Pinehurst Surgical Sinus Center Launches Pinehurst Balloon Sinuplasty Website 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 3Health News:NAPW Inducts Dr. Heather Stanley-Christian, Systems Chair/Maternal Fetal Medicine at Stroger Hospital, into Its VIP Professional Woman of the Year Circle 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3
... HILL, N.C., Feb. 19 With sales forces ... the constant,demand for rep time, winning a place ... response, leading pharma companies are relying on,specialized training ... process within the hospital environment, according to recent,research ...
... WYE ),announced today that The Honorable Stuart R. ... Maryland, has granted Wyeth,s motion for,summary judgment in the ... al -- an alleged vaccine injury case claiming that ... autistic., Previously, the Court had granted Wyeth,s motion ...
... PARK, Fla., Feb. 19 Transitionz Wellness,Boutique is ... or adult, who,is a cancer survivor, is going ... is trying to get well, and we are ... of the best products and services,including wigs, hats, ...
... A new technique developed by a University of Central ... bacterial infections patients have so they can be treated ... strains resistant to many drugs emerge, it becomes more ... would most effectively treat them. Such quick identifications become ...
... new study released,today found that pending congressional legislation ... technologies would likely result,in increased prices and "provide ... released today at the National Press Club by ... and senior fellow at,the American Enterprise Institute, and ...
... response to recent media,reports, Roche would like to reaffirm ... medication for the 2007-2008,flu season, and that physicians and ... flu strikes., Some news reports have indicated "shortages" ... in place to ensure that Tamiflu is readily,available. If ...
Cached Medicine News:Health News:Building an Effective Sales Force to Serve the U.S. Hospital Market 2Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 2Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 3Health News:Transitionz Wellness Boutique Launches with Grand Opening Discounts 2Health News:UCF technique promises to aid doctor's ability to identify, treat bacterial infections 2Health News:New Report Finds Mandatory Price Disclosure for Med Tech Would Likely Increase Prices 2Health News:Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide 2
... new modular Endourological Platform concept, the ... developped in extracorporeal lithotripsy: electroconductivity, with ... Sonolith Praktis can easily be coupled ... and ultrasound scanners for accurate localization ...
Used for temporary control of male urinary incontinence due to surgery or neurogenic disorder. Supplied non-sterile. Reusable. Intended for single patient use only....
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: